# US 9,750,810 B2 · Compositions and methods for treating chronic inflammation and inflammatory diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,810 B2 - Document ID: US9750810B2 - Status: Granted - Kind: B2 - Application number: 15/043,327 - Filed: 2016-02-12 - Published: 2016-06-09 - Granted: 2017-09-05 - Earliest claimed: 2010-10-29 - Assignees: Infirst Healthcare Limited - Applicants: Infirst Healthcare Limited - Inventors: Robin M. Bannister; John Brew; Wilson Caparros-Wanderely; Suzanne J. Dilly; Olga Pleguezeulos Mateo; Gregory A. Stoloff - Web page: https://patentgrep.com/patent/US9750810B2 ## CPC - A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 9/2013: {Organic compounds, e.g. phospholipids, fats} - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/60: Salicylic acid; Derivatives thereof - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) - A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/25: with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol - A61K 31/337: having four-membered rings, e.g. taxol - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. ## Claims ### Claim 1 A pharmaceutical composition comprising: a) about 10% to 30% of a propionic acid derivative NSAID by weight of the pharmaceutical composition; b) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition; c) about 20% to about 50% of a hard fat comprising a triglyceride or a triester of glycerol by weight of the pharmaceutical composition; and d) about 10% to about 30% of a liquid fat comprising a mono-glyceride by weight of the pharmaceutical composition, wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher. ### Claim 2 (depends on 1) The pharmaceutical composition according to claim 1, wherein the propionic acid derivative NSAID is about 20% to about 30% by weight of the pharmaceutical composition. ### Claim 3 (depends on 2) The pharmaceutical composition according to claim 2, wherein the propionic acid derivative NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition. ### Claim 4 (depends on 1) The pharmaceutical composition according to claim 1, wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen. ### Claim 5 (depends on 1) The pharmaceutical composition according to claim 1, wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen. ### Claim 6 (depends on 1) The pharmaceutical composition according to claim 1, wherein the hard fat or the triester of glycerol is in an amount from about 30% to about 50% by weight of the pharmaceutical composition. ### Claim 7 (depends on 6) The pharmaceutical composition according to claim 6, wherein the hard fat or the triester of glycerol is in an amount from about 35% to about 45% by weight of the pharmaceutical composition. ### Claim 8 (depends on 1) The pharmaceutical composition according to claim 1, wherein the hard fat or the triester of glycerol has a melting point of about 40° C. to about 46° C. ### Claim 9 (depends on 8) The pharmaceutical composition according to claim 8, wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of between 41° C. to 45° C. ### Claim 10 (depends on 9) The pharmaceutical composition according to claim 9, wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of about 43° C. ### Claim 11 (depends on 1) The pharmaceutical composition according to claim 1, wherein the liquid fat is in an amount from about 15% to about 25% by weight of the pharmaceutical composition. ### Claim 12 (depends on 1) The pharmaceutical composition according to claim 1, wherein the liquid fat further comprises a diglyceride, a triglyceride, or any combination thereof. ### Claim 13 (depends on 1) The pharmaceutical composition according to claim 1, wherein the monoglyceride is glyceryl monolinoleate. ### Claim 14 (depends on 1) The pharmaceutical composition according to claim 1, wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition. ### Claim 15 (depends on 14) The pharmaceutical composition according to claim 14, wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition. ### Claim 16 (depends on 15) The pharmaceutical composition according to claim 15, wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition. ### Claim 17 (depends on 16) The pharmaceutical composition according to claim 16 wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition. ### Claim 18 (depends on 1) The pharmaceutical composition according to claim 1, wherein the PEG polymer is a liquid PEG polymer. ### Claim 19 (depends on 18) The pharmaceutical composition according to claim 18, wherein the pharmaceutically-acceptable PEG polymer is less than about 2,000 g/mol. ### Claim 20 (depends on 19) The pharmaceutical composition according to claim 19, wherein the liquid PEG polymer is a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or a combination thereof.